Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

10.0%

1 terminated/withdrawn out of 10 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

4 recruiting2 with results

Enrollment Performance

Analytics

Phase 1

4(44.4%)

Early Phase 1

3(33.3%)

Phase 2

2(22.2%)

9Total

Phase 1(4)

Early Phase 1(3)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT07463196Phase 1Recruiting

A Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune System of ACI-19764 in Healthy Participants

Role: lead

NCT05462106Phase 1Recruiting

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

Role: lead

NCT06015841Phase 2Active Not Recruiting

A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's Disease

Role: lead

NCT06891703Early Phase 1Recruiting

[18F]ACI-15916 PET in α-synucleinopathies

Role: lead

NCT06891716Early Phase 1Recruiting

[18F]ACI-19626 PET in TDP-43 Proteinopathies

Role: lead

NCT06445465Early Phase 1Completed

Study to Evaluate a Potential PET Radioligand for Imaging Alpha-synuclein Deposits in the Brain

Role: collaborator

NCT04445831Phase 1Completed

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease

Role: lead

NCT04373616Phase 2Withdrawn

A Study of ACI-24 in Adults With Down Syndrome

Role: lead

NCT02738450Phase 1Completed

Safety, Tolerability and Immunogenicity of ACI-24 Vaccine in Adults With Down Syndrome

Role: lead

NCT05067192Completed

Optimization of Morphomer-based Alpha-synuclein PET Tracers

Role: collaborator

All 10 trials loaded